Biotechnology Contract Manufacturing Market Size is valued at USD 15.38 Bn in 2022 and is predicted to reach USD 30.87 Bn by the year 2031 at a 8.2% CAGR during the forecast period for 2023-2031.
A company called a contract manufacturing organization (CMO) is one that contracts out specialized services like drug manufacturing and manufacturing to other businesses in the biopharmaceutical sector. Biotechnology contract manufacturing plays a vital role in the biopharmaceutical industry, allowing companies to focus on research, development, and commercialization while relying on specialized partners for efficient and compliant manufacturing processes. This collaboration helps bring innovative biotech products to market, benefitting both the biotech firms and patients needing advanced therapies.
The increasing demand for biologics & biosimilars, the growing outsourcing of biologics manufacturing by biopharmaceutical companies, the increasing emphasis on personalized medicine, the expansion of partnerships between pharmaceutical companies and biologics contract manufacturers, and technological developments in the manufacturing industry all contribute to the market's growth.
Additionally, the market for biotechnology contract manufacturing will see growth due to the increase in demand for cell and gene therapies and the expansion of CMOs' biologics production capabilities. However, because of the loss of strategic control and the lack of management monitoring, large companies view outsourcing as risky. As a result, big pharmaceutical corporations choose to keep their manufacturing processes internal. This is anticipated to provide certain growth-related challenges for biotechnology contract manufacturing.
Competitive Landscape
Some Major Key Players In The Biotechnology Contract Manufacturing Market:
- Lonza (Switzerland)
- Samsung Biologics (South Korea)
- Thermo Fisher Scientific, Inc. (US)
- Catalent, Inc. (US)
- JSR Corporation (Japan)
- WuXi Biologics (China)
- AbbVie, Inc. (US)
- Boehringer Ingelheim International GmbH (Germany)
- Eurofins Scientific (Luxembourg)
- GenScript Biotech Corporation (US)
- AGC, Inc. (Japan)
- FUJIFILM Holding Corporation (Japan)
- Merck KgaA (Germany)
- Stelis
- Recipharm Ab
- Emergent
- Shanghai Fosun Pharmaceutical Co., Ltd.
- Lotte Biologics
- Hepalink Group
- Curia Global, Inc.
- Jrs Pharma
- Minapharm Pharmaceuticals
- Rentschler Biopharma Se
- Avid Bioservices, Inc.
- Abzena Ltd.
- Polyplus Transfection
- Midas Pharma GMBH
- Mabplex International Co., Ltd.
- Asahi Kasei Corporation
Market Segmentation:
The Biotechnology Contract Manufacturing Market is segmented on the basis of service, type, scale of operation, source, molecule, and therapeutic area. Based on the service, the market is segmented as Manufacturing, Formulation and Fill-Finish, Packaging and Labeling and Other services. Based on type, the market is segmented into Biologic Drug Substance Manufacturing and Biologic Drug Product Manufacturing.
By Scale of Operation, the market is divided into Commercial Operations and Clinical Operations. As per the source, the market is categorized into Mammalian Expression Systems and Non-Mammalian Expression Systems. By Molecule, the market is segmented into Monoclonal Antibodies, Cell Therapy & Gene Therapy, Antibody-Drug Conjugates (ADCs), Vaccines, Therapeutic Peptides & Proteins and Other Molecule Types. On the basis of therapeutic area, the market is categorized into Oncology, Autoimmune Diseases, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, Neurology and Other Therapeutic Areas.
Based On The Molecule, The Vaccines Segment Is Accounted As A Major Contributor In The Biotechnology Contract Manufacturing Market
The vaccine category commands a sizeable market share in the biotechnology contract manufacturing market. As monoclonal antibody therapy continues to advance, it is predicted to exhibit a similar pattern over the forecast period. The COVID-19 pandemic showed the manufacturing and outsourcing of vaccines had the potential to be a reliable source of income for businesses operating in the industry under investigation. After the COVID-19 vaccination, the addition of boosters is anticipated to make a favourable environment for the expansion of CMO vendors. The market growth under study is further aided by global campaigns by numerous governments and health organizations to offer immunizations to everyone.
The Mammalian Expression Systems Segment Witnessed Growth At A Rapid Rate
The mammalian expression systems segment is projected to grow rapidly in the global biotechnology contract manufacturing market. Market growth is anticipated to be pushed by the extensive research being done on the use of different sources and species for biopharmaceutical development. Enhancing the productivity and efficiency of the biopharmaceutical manufacturing process is the fundamental goal of these investigations. Because of the higher cost involved in getting goods from these sources, mammalian-based biomanufacturing contributed to a higher revenue share.
In The Region, The Asia Pacific Biotechnology Contract Manufacturing Market Holds A Significant Revenue Share
The Asia Pacific biotechnology contract manufacturing market is expected to record the maximum market share in revenue. The development of the biotechnology contract manufacturing market in the Asia Pacific is attributed to the region's robust pharmaceutical and biotech industries, the presence of a well-established pharmaceutical industry, the rising demand for biologics and biosimilars, and the increasing outsourcing of manufacturing services by pharmaceutical and biopharmaceutical firms.
Biotechnology Contract Manufacturing Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 15.38 Bn |
|
Revenue Forecast In 2031 |
USD 30.87 Bn |
|
Growth Rate CAGR |
CAGR of 8.2% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Service, By Type, By Scale of Operation, By Source, By Molecule, By Therapeutic Area |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Lonza (Switzerland), Samsung Biologics (South Korea), Thermo Fisher Scientific, Inc. (US), Catalent, Inc. (US), JSR Corporation (Japan), WuXi Biologics (China), AbbVie, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Eurofins Scientific (Luxembourg), GenScript Biotech Corporation (US), AGC, Inc. (Japan), FUJIFILM Holding Corporation (Japan), Merck KgaA (Germany), Stelis, Recipharm Ab, Emergent, Shanghai Fosun Pharmaceutical Co., Ltd., Lotte Biologics, Hepalink Group, Curia Global, Inc., Jrs Pharma, Minapharm Pharmaceuticals, Rentschler Biopharma Se, Avid Bioservices, Inc., Abzena Ltd., Polyplus Transfection, Midas Pharma GMBH, Mabplex International Co., Ltd., Asahi Kasei Corporation |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
